Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | J. H. Kim et al., J. Biol. Chem., Jun 2006; 281: 15747 - 15756 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene SI | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene EASY | publication | M. De Luca et al., J. Cell Sci., Jun 2014; 127: 2697 - 2708 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/siRNA) | K2 Transfection System | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | I. Sargiannidou et al., Neurogenetics, 2015, DOI 10.1007/s10048-015-0442-4 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Silvestri et al., Blood, May 2007; 109: 4503 - 4510 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | B. Anayat, Dissertation, 2021, University Konstanz | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | A. J. Jakobi et al., Nature Communications, 2020, 11: 440, doi.org/10.1038/s41467-020-14343-8 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Arias-del-Val, Cell Calcium, 2019, 77: 68–76, doi.org/10.1016/j.ceca.2018.12.004 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T.-H. Kang et al., Mol. Cell. Biol., Dec 2007; 27: 8533 - 8546 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | S. Gebremedhin et al., Biophysical J., 2014, 106(2): 625a | Link | ||
HEKT Epac-S-H187 |
Human embryonic kidney cell line, SV40 large T antigen inserted (derivative of 293T) | Human | urinary system | cell line | adherent | plasmid | K2 Transfection System | publication | C. I. McCarthy et al., J. Gen. Physiol., 2020, 152, 5: e201912492, doi.org/10.1085/jgp.201912492 | Link | |||
HEKT Epac-S-H187 |
Human embryonic kidney cell line, SV40 large T antigen inserted (derivative of 293T) | Human | urinary system | cell line | adherent | plasmid | K2 Transfection System | publication | A. Rodrıguez Gonzalez et al., The FEBS J., 2020, 288:229–243, doi:10.1111/febs.15344 | ||||
HEKT Epac-S-H187 |
Human embryonic kidney cell line, SV40 large T antigen inserted (derivative of 293T) | Human | urinary system | cell line | adherent | plasmid | K2 Transfection System | publication | E. Echeverría et al., Front. Pharmacol., 2020, 11: 113, doi: 10.3389/fphar.2020.00113 | Link | |||
HEK293TN |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | L. M. Williams, Dissertation, 2014, Royal College of Surgeons in Ireland | Link | ||
HEK293TN |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | F. Walter, Dissertation, 2014, Royal College of Surgeons in Ireland | Link | ||
HEK293S |
Human embryonic kidney cell line | Human | urinary system | cell line | adherent | plasmid | Metafectene EASY | publication | C.-Y. Lin et al., PLoS ONE, 2015, 10(4): e0123562; doi:10.1371/journal.pone.0123562 | Link | |||
HEK293N |
Human embryonic kidney cell line | Human | urinary system | cell line | adherent | plasmid | Metafectene | publication | T. Bourquard et al., J. Immunol., 2018, ji1701722, DOI: https://doi.org/10.4049/jimmunol.1701722 | ||||
HEK293-rB95.8 |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | J. Rac et al., PLoS ONE, 2015, 10(4): e0123645; doi:10.1371/journal.pone.0123645 | Link | ||
HEK293-rB95.8 |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | J. Rac et al., PLoS ONE, 2015, 10(4): e0123645; doi:10.1371/journal.pone.0123645 | Link | ||
HEK293-D2089 |
Human embryonic kidney cell line | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | V. Mordasini et al., Oncotarget, 2017, 8 ( 4): 6461-6474 | Link | ||
HEK293 F |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
||||
HEK293 EBNA1 |
Human embryonic kidney cell line stably expressing Epstein-Barr viral nuclear antigen 1 (EBNA1) (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene | publication | O. Gires et al., Anticancer Res, Nov 2004; 24: 3715 - 3722 | Link |